Gritstone bio, Inc. (GRTS) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

Shareholding (Jun 2024)

FII

8.22%

Held by 41 FIIs

DII

68.29%

Held by 23 DIIs

Promoter

7.02%

How big is Gritstone bio, Inc.?

22-Jun-2025

As of Apr 04, Gritstone bio, Inc. has a market capitalization of 0.00, categorizing it as a Micro Cap company, with net sales of 0.50 million and a net profit of -133.03 million over the latest four quarters. As of Dec'23, the company reported shareholder's funds of 51.85 million and total assets of 177.77 million.

Who are in the management team of Gritstone bio, Inc.?

22-Jun-2025

As of March 2022, Gritstone bio, Inc.'s management team includes Chairman Elaine Jones, CEO Andrew Allen, and several independent directors: Richard Heyman, Steve Krognes, Judith Li, Nicholas Simon, and Thomas Woiwode. This diverse team guides the company's governance and strategy.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Biotechnology

Market cap

USD 0 Million (Micro Cap)

P/E

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.42

Return on Equity

-599.54%

Price to Book

0.00

Revenue and Profits:

Net Sales:

0 Million

(Quarterly Results - Jun 2024)

Net Profit:

-23 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-100.0%

6 Months

-100.0%

1 Year

-100.0%

2 Years

-100.0%

3 Years

-100.0%

4 Years

-100.0%

5 Years

-100.0%

Gritstone bio, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-32.92%

EBIT Growth (5y)

-42.29%

EBIT to Interest (avg)

-76.11

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.42

Sales to Capital Employed (avg)

0.03

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

55.73%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

EV to EBIT

0.06

EV to EBITDA

0.07

EV to Capital Employed

-0.72

EV to Sales

-9.32

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-599.54%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Sideways

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Jun 2024

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 31 Schemes (16.47%)

Foreign Institutions

Held by 41 Foreign Institutions (8.22%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'24 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2024 is -75.00% vs -85.71% in Jun 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2024 is 33.71% vs -19.66% in Jun 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'24",
        "Jun'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.10",
          "val2": "0.40",
          "chgp": "-75.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-26.90",
          "val2": "-30.90",
          "chgp": "12.94%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.30",
          "val2": "1.00",
          "chgp": "30.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-23.40",
          "val2": "-35.30",
          "chgp": "33.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-499,157.90%",
          "val2": "-93,207.50%",
          "chgp": "-40,595.04%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2023 is -86.02% vs -80.09% in Dec 2022",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2023 is -15.71% vs -59.39% in Dec 2022",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Dec'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1.30",
          "val2": "9.30",
          "chgp": "-86.02%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-147.00",
          "val2": "-115.40",
          "chgp": "-27.38%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "4.00",
          "val2": "1.20",
          "chgp": "233.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-138.50",
          "val2": "-119.70",
          "chgp": "-15.71%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-116,178.80%",
          "val2": "-14,144.40%",
          "chgp": "-10,203.44%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'24 - YoY

Jun'24

Jun'23

Change(%)

Net Sales

0.10

0.40

-75.00%

Operating Profit (PBDIT) excl Other Income

-26.90

-30.90

12.94%

Interest

1.30

1.00

30.00%

Exceptional Items

0.00

Consolidate Net Profit

-23.40

-35.30

33.71%

Operating Profit Margin (Excl OI)

-499,157.90%

-93,207.50%

-40,595.04%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2024 is -75.00% vs -85.71% in Jun 2023

Consolidated Net Profit

YoY Growth in quarter ended Jun 2024 is 33.71% vs -19.66% in Jun 2023

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'23

Dec'23

Dec'22

Change(%)

Net Sales

1.30

9.30

-86.02%

Operating Profit (PBDIT) excl Other Income

-147.00

-115.40

-27.38%

Interest

4.00

1.20

233.33%

Exceptional Items

0.00

Consolidate Net Profit

-138.50

-119.70

-15.71%

Operating Profit Margin (Excl OI)

-116,178.80%

-14,144.40%

-10,203.44%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2023 is -86.02% vs -80.09% in Dec 2022

Consolidated Net Profit

YoY Growth in year ended Dec 2023 is -15.71% vs -59.39% in Dec 2022

All Annual Results

Company CV

About Gritstone bio, Inc.

Gritstone bio, Inc.

Biotechnology

Gritstone Oncology, Inc. is an immuno-oncology company that develops tumor-specific cancer immunotherapies to fight multiple cancer types. The Company focuses to identify and deploy therapeutic neo-antigens from individual patients' tumors to develop treatments for lung cancer. It provides Gritstone EDGE, which is a tumor-specific neo-antigen (TSNA) prediction platform that predicts the presence of a patient’s TSNA on tumor cells. It also develops and manufactures a patient-specific therapeutic to direct a robust thymus (T) cell response to those TSNA predicted to be presented on the patient’s tumor. In its GRANITE product candidate each of the viral prime and RNA boost immunizations contain a patient-specific set of predicted TSNA, and the viral prime and RNA boost in its SLATE product candidate series contains a fixed TSNA cassette that is designed for the subset of patients with tumor neoantigens.

Company Coordinates

Company Details

5858 Horton St Ste 210 , EMERYVILLE CA : 94608-2006

Tel: 1 510 8716100

https://gritstoneoncology.com/

Registrar Details

Gritstone bio, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Gritstone bio, Inc.?

Watch in Real-Time

Who are in the management team of Gritstone bio, Inc.?

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Jun 2024

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'24 - YoY

Annual Results Snapshot (Consolidated) - Dec'23

About Gritstone bio, Inc.

Company Coordinates